Novel Drug 'Graduates' in Breast Ca Trial (CME/CE)
SAN DIEGO (MedPage Today) -- A targeted therapy for breast cancer "graduated" to phase III eligibility for patients with HER2-positive/hormone receptor-negative disease, data from an ongoing trial showed.
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Breast Cancer | Cancer | Cancer & Oncology | Graduation | Health | HER2 | Hormones | International Medicine & Public Health